类风湿关节炎患者使用改善病情抗风湿药与不同糖尿病风险相关
该队列研究利用长庚研究数据库分析5530例无糖尿病的类风湿关节炎成人,随访至新发糖尿病(HbA1c≥7%)。生物制剂DMARD、甲氨蝶呤联合方案及其他传统DMARD治疗期间糖尿病风险显著低于甲氨蝶呤单药治疗期间;羟氯喹与糖尿病风险降低相关,肿瘤坏死因子-α抑制剂呈保护趋势。
要点
- 生物制剂DMARD治疗期间糖尿病风险显著低于甲氨蝶呤单药治疗期间(HR 0.51)。
- 甲氨蝶呤联合方案和其他传统DMARD治疗期间糖尿病风险也显著低于甲氨蝶呤单药治疗期间。
- 羟氯喹与糖尿病风险降低相关(HR 0.52),肿瘤坏死因子-α抑制剂呈保护趋势(HR 0.69)。
核心结论
- 类风湿关节炎患者使用不同改善病情抗风湿药时糖尿病风险水平可能不同。
研究设计与样本
- 队列研究,使用长庚研究数据库,纳入5530例无糖尿病的类风湿关节炎成人,随访至新发糖尿病(HbA1c≥7%)。
主要发现
- 546例参与者(9.87%)在2001年至2018年间发生糖尿病。
- 生物制剂DMARD治疗期间糖尿病风险显著低于甲氨蝶呤单药治疗期间(HR 0.51;95% CI 0.32至0.83)。
- 甲氨蝶呤联合方案治疗期间糖尿病风险显著低于甲氨蝶呤单药治疗期间(HR 0.50;95% CI 0.32至0.78)。
- 其他传统DMARD治疗期间糖尿病风险显著低于甲氨蝶呤单药治疗期间(HR 0.56;95% CI 0.37至0.84)。
- 羟氯喹与糖尿病风险降低相关(HR 0.52;95% CI 0.42至0.65),肿瘤坏死因子-α抑制剂呈保护趋势(HR 0.69;95% CI 0.46至1.03)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patients with rheumatoid arthritis are prone to developing diabetes, which may lead to various sequelae and even cardiovascular diseases, the most common cause of death in such patients. Previous research has shown that some rheumatoid arthritis treatments may help prevent the development of diabetes. This study aimed to investigate whether patients using disease-modifying anti-rheumatic drugs (DMARDs) may have different levels of risk for diabetes and to analyse other risk factors for diabetes. METHODS: This cohort study used data from the Chang Gung Research Database. 5530 adults with rheumatoid arthritis but without diabetes were eligible for the analysis. The endpoint of this study was new-onset diabetes, defined as an HbA1c value ≥7% during follow-up. The entire follow-up period was divided into monthly subunits. These 1-month units were then divided into methotrexate (MTX) monotherapy, any biological DMARDs (bDMARDs), MTX combination, other conventional DMARDs (cDMARDs) and non-DMARDs. RESULTS: A total of 546 participants (9.87%) developed diabetes between 2001 and 2018. The risk of diabetes was significantly lower in the bDMARD periods (HR 0.51; 95% CI 0.32 to 0.83), MTX combination periods (HR 0.50; 95% CI 0.32 to 0.78) and other cDMARD periods (HR 0.56; 95% CI 0.37 to 0.84) than in the MTX monotherapy periods. Individual drug analysis showed that hydroxychloroquine (HR 0.52; 95% CI 0.42 to 0.65) reduced the risk of diabetes. Tumour necrosis factor-α inhibitors (HR 0.69; 95% CI 0.46 to 1.03) tended to be protective. CONCLUSION: Patients with rheumatoid arthritis may have different levels of risk of diabetes depending on the treatment options.
引用
- Su YJ, Chen HM, Chan TM, et al. Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis. RMD Open. 2023. PMID: 37460274. doi:10.1136/rmdopen-2023-003045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。